CA
NZ
UK
AU
IND
US
Net income attributable to common shareholders was USD 82.3 million, or USD 0.23 per diluted share, against USD 99.7 million, or USD 0.27. The company tied the decrease mainly to lower net gains on property sales and lower other income and expense, net, partly …
Agent Analytics lets teams evaluate AI agent conversations, identify failure patterns and connect agent performance to outcomes such as conversion and retention. In September the company introduced Headless Amplitude, which brings product and user context into AI tools and is available on every plan. …
Grid segment revenue rose 41% to USD 76.67 million from USD 54.34 million and made up 82% of total revenue. The company said the increase came from adding Comtrafo, a Brazil-based maker of large power and distribution transformers acquired on December 5, 2025, along …
Reported production was approximately 450,000 BOE per day, and adjusted production, which excludes Egypt noncontrolling interest and tax barrels, was 381,000 BOE per day. U.S. oil production averaged 128,000 barrels per day, 4,000 barrels above guidance, which the company linked to high uptime, earlier …
Fuel revenue was USD 1,146.9 million, up 34.0%, and related party fuel revenue was USD 718.4 million, up 18.0%. Total gallons sold were 478.3 million against 523.0 million. Total operating expenses were USD 1,863.3 million against USD 1,460.8 million.
At September 30, USD 394.3 million remained available under the program before the October increase. Net cash used in financing activities was USD 2,873.0 million for nine months, which included USD 2.8 billion of share repurchases, against USD 2.1 billion in the same period …
Adjusted admissions increased 2.9% to 91,933, which followed a 2.5% increase in the second quarter. Admissions were 41,899 against 41,862, a 0.1% increase after a 1.0% decline in the second quarter. Emergency room visits were 163,909, up 1.7% from 161,198.
Revenue of USD 38.2 million was reported against USD 35.1 million. Management said higher activated carbon sales volumes added about USD 3.8 million and other chemicals added USD 0.2 million, while a lower average selling price and product mix offset USD 0.6 million and …
The company markets ZORYVE as a once-daily, steroid-free topical PDE4 inhibitor across plaque psoriasis, seborrheic dermatitis and atopic dermatitis. In June 2026 it launched an expanded U.S. indication for ZORYVE cream 0.3% in children down to age 2, and in October 2026 it launched …
Total executed contracts and awarded orders stood at a record USD 2.6 billion at September 30, 2026, up 42% from a year earlier. Trailing twelve-month net new orders were over USD 1.8 billion at a book-to-bill ratio of 1.6 times.
Please wait processing your request...